Metformin is the mainstay of treatment of type 2 diabetes. However, there has been significant concern on prescribing metformin in patients with renal impairment as a result of metformin-associated lactic acidosis (MALA). Recent studies have cast doubt on the existence of MALA purely related to metformin use. Medsafe recently initiated changes to datasheet so lower doses of metformin could be used in patients with GFR down to 15ml/min. In this paper we outline the context and implications of this change.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
metformin patients
8
refining metformin
4
metformin prescribing
4
prescribing zealand
4
metformin
4
zealand metformin
4
metformin mainstay
4
mainstay treatment
4
treatment type
4
type diabetes
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!